Login to Your Account

Clinic Roundup

Thursday, May 31, 2012
• Repros Therapeutics Inc., of The Woodlands, Texas, said the FDA advised the firm it must complete an integrated safety analysis of completed studies of oral Proellex and submit a report for review prior to any additional trials testing oral administration of telapristone acetate, Proellex's active ingredient.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription